Plasma assays combining p-tau217 and Aβ42/40 accurately confirm AD, supporting patient eligibility for anti-amyloid disease-modifying therapies.
A study reveals that starting benzodiazepines or antipsychotics in hospice patients with dementia significantly increases 180-day mortality, urging careful prescribing.
An 18-year multicohort study found that smokers who quit even in later life showed 20% slower memory decline vs those who continued to smoke.
Roche's Elecsys pTau181 test has a 97.9% negative predictive value to rule out amyloid pathology, which will improve referral decisions and expedite treatment.
As dementia care grows more complex and more promising, the role for front-line clinicians is becoming more nuanced and more essential.
The ReCODE program targets metabolic, infectious, immune, vascular, and toxic exposures, elements that underlie both mood and cognition, study authors said.
The FDA has granted fast track designation to BMS-986446, an anti–microtubule binding region tau antibody in phase 2 trials for early Alzheimer disease.
The European Commission granted marketing authorization for the Lilly mAb based on data from the phase 3 TRAILBLAZER-ALZ 2 and 6 clinical trials.
A study of more than 559 000 adults and 2.4 million genetic samples found that alcohol consumption of any amount increases dementia risk, challenging prior evidence of protective effects from light drinking.
FDA grants Fast Track designation to etalanetug, a promising tau-targeting antibody for Alzheimer disease that could expand treatment options for the neurodegenerative disease.